system. The State of NY is little better. BCG is available all over the world and not in NY.
Shoot guns or heroin if you wish. People with autoimmune diseases et al should have easy access to BCG
If Obama cared a little about healthcare he would read eg faustmanlab.org and pubmed.org and help.
Can't expect much of a lawyer?
Hello Mr. >>>>>
I
am sorry but this office will not administer the BCG vaccine. Please
contact the Department of Health for any further advise.
Susan Conforti
Medical Office Manager
Nassau South Walk-In Medical Care
(O) 516-558-7858
(F) 516-812-3975
The
information contained in this transmission and any attachments are for
the sole use of the intended recipient(s) and may be confidential,
privileged, copyrighted or may constitute intellectual property. Any
unauthorized review, use, disclosure or distribution of this
transmission and any attachments is strictly prohibited. If you have
received this transmission in error, please contact the sender and
destroy all paper and/or electronic copies of this transmission.
From: leonard
To:
nassausouth@yahoo.com
Sent: Monday, August 20,
2012 9:44 PM
Subject: [Fwd: Update
from the Faustman Lab]
Dear
Susan:
I never heard back from you about BCG.
I think you will
find the attached fascinating.
BCG has been given to billions of
people and I would like to be one of them.
New
Paper from the
Faustman Lab: Proof-of-Concept, Randomized, Controlled Clinical Trial
of Bacillus-Calmette-Guerin for Treatment of Long-term Type 1 Diabetes
|
|
 |
August 20, 2012
Clinical Paper on
Phase I Trial with BCG Is Now Published
The findings
from this double-blinded clinical trial, even at this early testing
stage in humans, show that the generic BCG vaccine can raise the levels
of an immune system modulator (called tumor necrosis factor, or TNF) to
kill the disease-causing T cells that attack the pancreas and help to
temporarily restore insulin secretion in patients with long-term type 1
diabetes.
We are trying
to create a regimen that will reverse type 1 diabetes, even for people
in the most advanced stages of the disease. With the Phase I clinical
trial data, we believe we have validated in humans the treatment
pathway we originally reported in mice. We expected to verify the
safety of the BCG vaccine in type 1 diabetes in this Phase I study, as
well as now show early signs of BCG efficacy. Our findings show that a
simple, inexpensive vaccine can modify the autoimmunity underlying type
1 diabetes by selectively killing only the disease-causing T
cells, leading to at least some restoration of pancreatic beta-cell
insulin function. In Phase II human clinical testing of BCG, we
hope that more
frequent or higher BCG dosing will help the body eliminate the
disease-causing T cells for a longer time, which we hope will restore
insulin production to a greater degree and for a more sustained period
of time than in the Phase I study.
Dr. Paul Burn, PhD,
chair
and director emeritus of the Sanford Project and professor of
Pediatrics at the Sanford School of Medicine at the University of South
Dakota, had this to say about our results: "Dr. Faustman and her team's
clinical research data indicate that modifying the autoimmunity
underlying type 1 diabetes allows for a safe and temporary restoration
of insulin-secreting beta-cell function in patients with established
type 1 diabetes. Restoring beta-cell function is a promising first step
towards a cure. During my tenure in industry, at Sanford Health and at
the Juvenile Diabetes Research Foundation, I have seen how hard it is
to get a project from mice into humans, and these are very impressive
results."
These human
clinical trials are unique in testing an immune intervention in
advanced type 1 diabetes (not just new-onset disease), using an
inexpensive and safe generic vaccine, understanding the mechanism by
which the treatment works to selectively eliminate the unwanted,
disease-causing T cells, and being able to successfully track efficacy
with careful blood monitoring. These factors will contribute to
speeding our progress as we move forward in clinical testing.
Currently, $11
million of the total $25.2 million needed has been raised for a Phase
II study. Please consider making a donation to support
this groundbreaking work by visiting www.faustmanlab.org/support/support.html.
Denise Faustman,
MD, Ph.D.
|
|
|
|
Faustman Lab at Mass General
Massachusetts General Hospital Charlestown, Massachusetts 02129
diabetestrial@partners.org
617-726-4084
|
|
|
|
|
|
|
|
Hello Mr.<<<<
I
am sorry but this office will not administer the BCG vaccine. Please
contact the Department of Health for any further advise.
Susan Conforti
Medical Office Manager
Nassau South Walk-In Medical Care
(O) 516-558-7858
(F) 516-812-3975
The
information contained in this transmission and any attachments are for
the sole use of the intended recipient(s) and may be confidential,
privileged, copyrighted or may constitute intellectual property. Any
unauthorized review, use, disclosure or distribution of this
transmission and any attachments is strictly prohibited. If you have
received this transmission in error, please contact the sender and
destroy all paper and/or electronic copies of this transmission.
From: leonard <pointreyes@verizon.net>
To: nassausouth@yahoo.com
Sent: Monday, August 20, 2012 9:44 PM
Subject: [Fwd: Update from the Faustman
Lab]
Dear Susan:
I never heard back from you about BCG.
I think you will find the attached fascinating.
BCG has been given to billions of people and I would like to be one of them.
jackson leeds
223-8407
New Paper from the
Faustman Lab: Proof-of-Concept, Randomized, Controlled Clinical Trial
of Bacillus-Calmette-Guerin for Treatment of Long-term Type 1 Diabetes
|
|
 |
August 20, 2012
Clinical Paper on Phase I Trial with BCG Is Now Published
The findings
from this double-blinded clinical trial, even at this early testing
stage in humans, show that the generic BCG vaccine can raise the levels
of an immune system modulator (called tumor necrosis factor, or TNF) to
kill the disease-causing T cells that attack the pancreas and help to
temporarily restore insulin secretion in patients with long-term type 1
diabetes.
We are trying
to create a regimen that will reverse type 1 diabetes, even for people
in the most advanced stages of the disease. With the Phase I clinical
trial data, we believe we have validated in humans the treatment
pathway we originally reported in mice. We expected to verify the
safety of the BCG vaccine in type 1 diabetes in this Phase I study, as
well as now show early signs of BCG efficacy. Our findings show that a
simple, inexpensive vaccine can modify the autoimmunity underlying type
1 diabetes by selectively killing only the disease-causing T cells, leading to at least some restoration of pancreatic beta-cell insulin function. In Phase II human clinical testing of BCG, we hope that more
frequent or higher BCG dosing will help the body eliminate the
disease-causing T cells for a longer time, which we hope will restore
insulin production to a greater degree and for a more sustained period
of time than in the Phase I study.
Dr. Paul Burn, PhD, chair
and director emeritus of the Sanford Project and professor of
Pediatrics at the Sanford School of Medicine at the University of South
Dakota, had this to say about our results: "Dr. Faustman and her team's
clinical research data indicate that modifying the autoimmunity
underlying type 1 diabetes allows for a safe and temporary restoration
of insulin-secreting beta-cell function in patients with established
type 1 diabetes. Restoring beta-cell function is a promising first step
towards a cure. During my tenure in industry, at Sanford Health and at
the Juvenile Diabetes Research Foundation, I have seen how hard it is
to get a project from mice into humans, and these are very impressive
results."
These human
clinical trials are unique in testing an immune intervention in
advanced type 1 diabetes (not just new-onset disease), using an
inexpensive and safe generic vaccine, understanding the mechanism by
which the treatment works to selectively eliminate the unwanted,
disease-causing T cells, and being able to successfully track efficacy
with careful blood monitoring. These factors will contribute to
speeding our progress as we move forward in clinical testing.
Currently, $11 million of the total $25.2 million needed has been raised for a Phase II study. Please consider making a donation to support this groundbreaking work by visiting www.faustmanlab.org/support/support.html.
Denise Faustman, MD, Ph.D.
|
|
|
|
Faustman Lab at Mass General
Massachusetts General Hospital
Charlestown, Massachusetts 02129
diabetestrial@partners.org
617-726-4084
|
|
|
|
|
|
|
|
|
![The University of Melbourne [logo]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uKE_Grt2ZzaU2UFKAlTsvV9d03f1UYLDRP21Fo5CNSbANv_SqGISRgM0d1QLI924xEusw3ghxVzw642T8DB0yE8npdxliZufwv47krWP5VTopRaWUpNQGR5UtGupUjhI8bOJqu2tuOc-a9AERo2MtQaU3lgbhpv_WEMSCs-_55mbo=s0-d)
